Navigation Links
Lupus Research Institute Launches NYC's First Lupus Trials Fair
Date:9/15/2014

NEW YORK, Sept. 15, 2014 /PRNewswire/ -- Over 200 patients, families, physicians and scientists came together under one roof Saturday to learn, interact and participate in the drive for better lupus treatments at New York City's first Lupus Trials Fair launched by the Lupus Research Institute (LRI) and the S.L.E. Lupus Foundation.  Attendees interacted directly with researchers at eight of NYC's leading institutions -- sharing experiences, ideas and needs and learning about more than 80 opportunities to participate in studies needed to transform patient lives. 

LRI President and CEO Margaret Dowd emphasized, "Everyone in the lupus community – patients, scientists, researchers, healthcare providers, bio-pharmaceutical industry – each plays a role if we are to develop safer, effective therapies while moving toward prevention and a cure.  Only one drug has been approved for lupus in over 50 years.  But more promising treatments for lupus are in development than ever before, and we need all hands on deck to get them tested and approved. Lupus patients hold the greatest power to accelerate new drug development; it is their perspective, engagement and leadership that make the greatest difference. Without patient participation, there is no clinical research." 

Why Participate?

Presenters explained the different types of trials, many of which do not involve experimental therapies, as well as the critical need for volunteers with and without the disease. Attendees learned how taking part in a clinical study allows patients to take an active role in their own healthcare,  receive quality care from top professionals and gain access to cutting-edge treatments while advancing lupus research. 

The urgent need for better treatments was powerfully highlighted in the new photo exhibit Lupus through the Lens previewed here before its presentation at the upcoming American College of Rheumatology annual meeting. Created by patients as a means of therapeutic expression, the photos visualize the devastation of what is often an invisible disease.  

Lupus patient Kaamilah Gilyard strongly encourages others to get involved. "Participating in a clinical study makes me feel both hopeful and helpful. I know I'm doing something truly meaningful that could save my own life and the lives of so many others."

The NYC Lupus Trials Fair is the first of an expanded program planned in the country's major cities and high-population states through members of LRI's National Patient Coalition.  Formed by patients and families, the Coalition now marks 10 years of successful advocacy, education, and fundraising for lupus research.

As additional Fairs are scheduled, announcements will be posted on LupusTrials.org, the LRI's dedicated website for education on clinical research.  The customized search tool on the website helps patients find lupus studies that might be right for them to discuss with their physicians. 

About Lupus
Systemic lupus erythematosus (SLE), or lupus, is a chronic, complex and serious autoimmune disease affecting more than 1.5 million Americans, primarily women in the prime of their lives. In lupus, the immune system, which is designed to protect against infection, creates antibodies that attack the body's own tissues and organs—the kidneys, brain, heart, lungs, blood, skin, and joints. Lupus is difficult to diagnose, difficult to treat, and a leading cause of premature cardiovascular disease, kidney disease and stroke among young women.

About the LRI
The Lupus Research Institute (LRI), the leading private supporter of novel research in lupus, pioneers discovery and champions scientific creativity as it demonstrates the power of innovation to transform patients' lives. Founded by families and shaped by leading scientists, the Institute has generated over $170-million for cutting edge lupus research, delivering many of the most pivotal scientific breakthroughs of the past decade. With its National Patient Coalition of regional lupus organizations, the Lupus Research Institute improves patient care by promoting research awareness, education and advocacy as it advances toward Life Without Lupus. For more information, visit www.lupusresearchinstitute.org.


'/>"/>
SOURCE Lupus Research Institute
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. New Published Guidelines to Help Physicians Diagnose and Treat Lupus Kidney Disease
2. Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for Discoid Lupus
3. Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
4. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
5. Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
6. Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod
7. Two Of The Nations Top Specialists In Lupus, Drs. Swamy Venuturupalli & Daniel Wallace, Join In Expanding Research On Auto-Immune Diseases
8. For the Treatment of Lupus, the Emerging Therapies Epratuzumab and Lupuzor Have the Potential to Offer Improvements Over IV Belimumab in Reducing Disease Activity
9. Lupus Foundation of Florida Applauds Support for Biosimilars Legislation
10. Lupus Research Institute Hosts First International Conference to Advance New Treatments for Lupus Nephritis
11. Rheumatologists in the EU5 Give the Highest Satisfaction and Performance Ratings to Rituxan and Benlysta for the Treatment of Systemic Lupus Erythematosus (SLE)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2018)... (PRWEB) , ... August 02, 2018 , ... UMD Professor ... to $7.7 million over 5 years from the National Institute of Allergy and Infectious ... research program to understand the immune responses of ticks that contribute to the spread ...
(Date:8/2/2018)... ... , ... Clay and Associates DDS, PLC is excited to welcome Dr. Tyler ... John Clay and Dr. Shaun O’Neill as an associate dentist to the practice. , ... patients' dental hygiene, encapsulates the core values of the professional dental team at Clay ...
(Date:8/2/2018)... , ... August 02, 2018 , ... ... humanitarian efforts, is an inspiring, international leader of sustainable advocacy. Sharon Kleyne, host ... Pharma®, The Power of Water® & Your Health sponsored by Nature’s Tears® EyeMist® ...
Breaking Medicine Technology:
(Date:8/14/2018)... ... August 14, 2018 , ... Health & hygiene ranked eighth ... is the largest study of brands based on emotions. In the U.S., Olay again ... 10 for the health & hygiene industry were: Listerine, Nivea, Gillette, Colgate, Head & ...
(Date:8/11/2018)... ... August 10, 2018 , ... TopConsumerReviews.com recently awarded a five-star ... gout? This painful, persistent condition originates in the liver and is characterized by ... acid. Other contributing factors may be medication side effects, overweight, and unhealthy diet. ...
(Date:8/9/2018)... ... August 09, 2018 , ... Lyme disease is one of the ... to an estimated 329,000 – a 25-fold increase since surveillance began in 1982. According ... be found all 50 states and the District of Columbia. Yet, Lyme and other ...
(Date:8/7/2018)... ... August 07, 2018 , ... Josh Sprague, Founder and CEO of ... preview for the upcoming Leadville 100 MTB. , Accompanied by colleague Marvin Sandoval ... he has called “one of the most iconic mountain bike race courses in the ...
(Date:8/3/2018)... ... , ... On August 2, 2018 the JPML ordered that the Zostavax MDL ... LLC has been litigating Zostavax injuries since 2011. , ... for the thousands of people injured by Zostavax, a vaccine given to adults to ...
Breaking Medicine News(10 mins):